A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome

Non-interventional, Multicenter Retrospective Study of the Effectiveness and Safety of Teduglutide (Revestive®) in Short Bowel Syndrome Adult Patients in Spain (T-Rex Study)

The main aims of the study are to assess the safety profile of teduglutide (Revestive®) as well as how many people with Short Bowl Syndrome experience a reduction of parenteral support when treated with teduglutide (Revestive®).

This study is about collecting existing data only; participants will not receive teduglutide (Revestive®) as part of this study. No new information will be collected during this study. Only data already available in the hospital records will be reviewed and collected for this study.

Participants do not need to visit their doctor in addition to their normal visits.

Inclusion Criteria:

• Participants >= 18 years of age diagnosed with intestinal failure due to SBS as a result of intestinal resection.
• SBS-IF participants treated with teduglutide according to Summary of Product Characteristics (SmPC).
• Patients who receive or have received teduglutide for at least six months at the date of inclusion (from treatment initiation to inclusion date, date of discontinuation, death for any cause or loss of follow-up).
• When required by the ethics committee of the center: participants who have signed the informed consent form (ICF) to participate in the study.

Exclusion Criteria:

- Participants who do not meet the inclusion criteria.